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The development of constrained peptides represents an emerging strategy to generate peptide based
probes and hits for drug-discovery that address challenging protein–protein interactions (PPIs). In this
manuscript we report on the use of a novel a-alkenylglycine derived amino acid to synthesise
hydrocarbon constrained BH3-family sequences (BIM and BID). Our biophysical and structural analyses
illustrate that whilst the introduction of the constraint increases the population of the bioactive a-helical
conformation of the peptide in solution, it does not enhance the inhibitory potency against pro-
apoptotic Bcl-xL and Mcl-1 PPIs. SPR analyses indicate binding occurs via an induced ﬁt mechanism
whilst X-ray analyses illustrate none of the key interactions between the helix and protein are disturbed.
The behaviour derives from enthalpy–entropy compensation which may be considered in terms of the
ground state energies of the unbound constrained and unconstrained peptides; this has implications for
the design of preorganised peptides to target protein–protein interactions.Introduction
Protein–protein interactions (PPIs) mediate virtually all biolog-
ical processes and as such there is a demand for methods that
can modulate these interactions in a selective, dose-dependent
and temporal manner. PPIs are considered challenging targets
for molecular intervention,1 as they typically involve interaction
of large, comparatively featureless protein surfaces. Inhibition
of PPIs mediated by a-helices represents an area of chemical
biology that has become tractable in terms of ligand develop-
ment, with a variety of small molecule, constrained peptides
and helix mimetics under development.2 Constraining peptides
in a helical conformation has been reported to confer benets
that include enhanced protease resistance, stability in cells,
increased cellular uptake3 and enhanced biophysical properties
in comparison to wild-type peptide sequences.4,5 More speci-
cally, constrained peptides are anticipated to bind their targets
with higher potency due to a reduced entropic cost of adopting
a bioactive a-helical conformation. Multiple methods have beenodhouse Lane, Leeds LS2 9JT, UK. E-mail:
iology, University of Leeds, Woodhouse
ds@leeds.ac.uk
niversity of Leeds, Woodhouse Lane, Leeds
ESI) available. CCDC 1057141. For ESI
other electronic format see DOI:used to constrain peptides,6 that make use of helix favouring
amino acids,7,8 helix nucleating motifs,9 disuldes,10 lactam
bridges,11,12 hydrogen bonding surrogates,13,14 hydrocarbon
linkages (colloquially termed “staples”)4,5,15–20 and other modi-
cations;21–27 proline is particularly noteworthy as a helix
breaker28,29 but may also act to cap a helix.30 Hydrocarbon
constraints are incorporated by replacing native amino acids
with an a-a-disubstituted alkenyl amino acids followed by
ruthenium catalysed olen metathesis to create the irreversible
constraint.31–33 By carefully choosing the residues to replace, one
should be able to create the constraint whilst maintaining the
essential residues required for interaction with the target
protein.
We recently introduced the monosubstituted amino alkenyl
amino acid as an eﬀective reagent for creation of a hydrocarbon
constraint.34 This amino acid should couple more eﬀectively in
conventional Fmoc mediated peptide synthesis and the resul-
tant constraint may be advantageous over the disubstituted
amino acid in terms of removing steric clashes with the target.35
In this work we investigate the use of a monosubstituted amino
acid in the creation of a hydrocarbon constraint using Bcl-2/
BH3 family PPIs as a model (Fig. 1a and b). This family of
proteins play a pivotal role in the regulation of apoptosis,36 play
a major role in cancer development/progression37 and represent
key targets for anticancer drug-discovery38 The regulation of
apoptosis exploits varying specicity and selectivity of pairwise
interactions within the Bcl-2 family interactome (Fig. 1a).39,40
The canonical structural motif involves a BH3 domain from oneThis journal is © The Royal Society of Chemistry 2016
Fig. 1 Bcl-2 family PPIs (a) schematic depicting selectivity preferences
for interaction of the modulators and pro-apoptotic family members
with the anti-apoptotic family members (dashed lines denote
promiscuous recognition, full lines denote selective interactions). (b)
Crystal structure (PDB ID: 3FDL) of Bcl-xL/BIM interaction (Bcl-xL as
a surface and BIM BH3 peptide shown in red).
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View Article OnlineBcl-2 family member adopting a helical conformation and
binding to a BH3 binding cle of another partner (Fig. 1b). In
our original study, we observed an increase in peptide helicity
and enhanced enzymatic stability with the use of the mono-
substituted amino acid for one member of the Bcl-2 eﬀector sub
family (BID). In our hands and in contrast to prior proof-of-
concept studies,15,41 the potency of inhibition for Bcl-xL/BAK was
comparable to that of the wild type (WT), and variant peptides
bearing aminoisobutyric acid or the disubstituted amino acid at
the stapling positions.34 The purpose of this current study was
to understand whether this behaviour was unique to BID and to
establish a more detailed explanation for the seemingly para-
doxical observation that a net increase in the population of the
bioactive conformation failed to yield an increase in the binding
aﬃnity to the target protein.Results
Synthesis
In our initial investigation we introduced a hydrocarbon
constraint into the BID-BH3 peptide to compare the use of
a monosubstituted amino acid with the more widely exploited
disubstituted amino acid.34 We synthesised (S)-pentenylglycine
using the method developed by Belokon and co-workers;42 the
stereochemistry of the amino acid was conrmed by single
crystal diﬀraction studies on the precursor nickel complex (see
ESI†). For a full comparison, we also synthesized the disubsti-
tuted amino acid and incorporated this, the monosubstituted
amino acid and aminoisobutyric acid (Aib) at appropriate
positions in the BID sequence (replacing 92Gln and 96Ser). In the
current study a series of additional peptides were either sourcedThis journal is © The Royal Society of Chemistry 2016commercially or synthesized in house (Table 1) including Bcl-2
family WT peptides, peptides labelled with a uorescent group
(uorescein or BODIPY) to facilitate direct binding measure-
ments and a series of constrained BIM peptides. We selected
BIM BH3, one of the key BH3 members, as it has a high aﬃnity
for all of the anti-apoptotic proteins (Fig. 1a).39,40 Peptide
“staples” were introduced at positions previously identied as
optimal.15,41,43 The peptides were prepared using standard Fmoc
solid phase peptide synthesis protocols using low loading Rink
amide MBHA resin to aﬀord C-terminally amidated peptides.34
Alkenyl amino acid containing peptides were subjected to olen
metathesis to generate constrained peptides. In order to prevent
any complications arising from interaction of the Grubbs'
catalyst with the FITC label, the metathesis was performed
before the nal Fmoc deprotection and coupling of FITC.
Constrained BIM peptides were synthesised by replacing 94Arg
and 98Glu with non-natural amino acids.44 BIM-DM (disubsti-
tuted metathesized) and BIM-MM (monosubstituted metathe-
sized) peptides were synthesized on a 0.075 or a 0.1 mmol scale
respectively; the rst 8 residues were built using an automated
peptide synthesiser and, subsequently, unnatural amino acids
and residues in between were coupled manually with the
remaining 8 residues coupled using automated methods. Aer
on-resin Grubbs' metathesis, the BIM-MM and BIM-DM
peptides were obtained in high purity with no observed dele-
tions and puried using semi-preparative HPLC.Peptide conformation
Consistent with our preliminary report, incorporation of
a constraint in the BID or BIM peptides induced helicity,
independent of the use of a mono or disubstituted amino acid
and was not aﬀected by the presence of FITC. FITC labelled
peptides retained the enhanced helicity in circular dichroism
(CD) spectra observed for their unlabelled counterparts
(Fig. 2a), with 74% (FITC-BID-MM) and 70% (FITC-BID-DM)
helicity in comparison to the FITC-BID-WT, which had 23%
helicity. The spectra were found to be concentration indepen-
dent (see ESI†). Making an assumption that the diﬀerence in
helicity is proportional to the diﬀerence in stability between
constrained and WT allows DDG  2.9 kJ mol1 to be estimated
for introduction of the hydrocarbon constraint. The constrained
BIM peptides also showed an increase in helicity as determined
by CD, with 57% of BIM-DM and 59% helicity within BIM-MM
in comparison to the BIM-WT of 20% (Fig. 2b). Again making
assumptions as for BID allowed DDG  2.6 kJ mol1 to be
estimated for introduction of the constraint.
Thermal unfolding experiments were carried out to under-
stand how well the constraint maintains the helical conforma-
tion upon denaturation. The mean residue ellipticity was
compared against the unfolded wild type as a function of
temperature to evaluate the extent that it resists unfolding.
There were minor changes in signal at 222 nm of both BID-MM
and BID-DM, whereas the wild-type BID peptide was mostly
unfolded at the start of the experiment (Fig. 2c, d). Due to the
presence of the hydrocarbon linker, constrained peptides could
not be completely unfolded into a random coil conformation;Chem. Sci., 2016, 7, 3694–3702 | 3695
Table 1 Peptide sequences used in this work. (WT – wild-type, MM –
monosubstituted metathesised, DM – disubstituted metathesised, AIB
– aminoisobutyric acid substituted, Ahx – amino hexanoic acid)
Peptide Sequence
BAK WT Ac-Ahx-G72QVGRQLAIIGDDINR87-NH2
BID WT Ac-E80DIIRNIARHLAQVGDSNLDRSIW
102-NH2
BAD WT Ac-L104WAAQRYGRELRRMSDEFEGSFDKL128-NH2
BIM-WT Ac-I56WIAQELRRIGDEFNAYYARR56-NH2
NOXA-
B WT
Ac-P68ADLKDECAQLRRIGDKVNL87-NH2
BID-MM Ac-E80DIIRNIARHLAXVGDXNLDRSIW
102-NH2
BID-DM Ac-E80DIIRNIARHLAZVGDZNLDRSIW
102-NH2
BID-AIB Ac-E80DIIRNIARHLA(Aib)VGD(Aib)NLDRSIW
102-NH2
BIM-MM Ac-I56WIAQELRXIGDXFNAYYARR76-NH2
BIM-DM Ac-I56WIAQELRZIGDZFNAYYARR76-NH2
BODIPY-
BAK
BODIPY-Ahx-G72QVGRQLAIIGDDINR87-NH2
FITC-BID-
WT
FITC-Ahx-E80DIIRNIARHLAQVGDSNLDRSIW
102-NH2
FITC-BID-
MM
FITC-bAla-E80DIIRNIARHLAXVGDXNLDRSIW
102-NH2
FITC-BID-
DM
FITC-bAla-E80DIIRNIARHLAZVGDZNLDRSIW
102-NH2
FITC-BID-
AIB
FITC-bAla-E80DIIRNIARHLA(Aib)VGD(Aib)NLDRSIW
102
-NH2
FITC-NOXA-
B WT
FITC-Ahx-P68ADLKDECAQLRRIGDKVNL87-NH2
Fig. 2 Conformational analysis of BH3 peptides by circular dichroism
(CD). (a) Fluorescein labelled BID peptides (b) BIM peptides (c) thermal
unfolding CD spectra for BID-MM. (d) Changes in MRE value at 222 nm
for BID peptides with temperature.
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View Article Onlinethe thermal unfolding reduced the helical content of the con-
strained BID peptides to 37–40% (Fig. 2d). Notably, the transi-
tion does not progress through a sigmoidal curve characteristic
of two state co-operative unfolding; this gradual transition is
expected for a short helix with low enthalpy of folding.45Binding of constrained peptides to Bcl-2 family members
To prole the binding behaviour of the constrained peptides we
tested them in both competition displacement assays and direct
binding assays. We selected Bcl-xL and Mcl-1 as targets because
they have diﬀerential binding properties towards BH3 only
sequences.39,40 Of particular interest was the potential for the
introduction of a constraint to have diﬀerential eﬀects on
protein specicity/selectivity. Initially, we conrmed prior
results by testing the binding of labelled WT BH3 peptides
(BAK, BID and NOXA-B) to Bcl-xL and Mcl-1 using uorescence
anisotropy (FA) and through FA competition assays in which
unlabelled peptides are used to displace labelled BAK or NOXA-
B from the Bcl-xL or Mcl-1 respectively (see ESI†). We next tested
the constrained peptides in inhibition assays (Fig. 3a and b and
Table 2). For BID, no eﬀect on inhibitory potency against Bcl-xL/3696 | Chem. Sci., 2016, 7, 3694–3702BODIPY-BAK in comparison to the BID-WT was observed (BID-
WT 1.44 mM, BID-MM 0.62 mM, BID-DM 1.14 mM and the BID-
Aib 1.14 mM). We then tested BID-MM and BID-DM against Mcl-
1/FITC-NOXA-B in a FA based competition assay. In competition
against this diﬀerent Bcl-2/BH3 pairing, BID-MM was less
potent, with an IC50 of 1.6 mM in comparison to 0.39 mM with
BID-WT, whilst BID-DM was slightly better than BID-MM, with
an IC50 of 0.8 mM.
The constrained BIM peptides were also tested in competi-
tion assays against Bcl-xL/BODIPY-BAK and Mcl-1/FITC-NOXA-B
interactions. In the case of Bcl-xL/BODIPY-BAK, the constrained
BIM variants were less potent, IC50 ¼ 320 nM for BIM-WT, IC50
¼ 11.9 mM for BIM-MM and IC50 ¼ 4 mM BIM-DM (Fig. 4a). This
result was surprising, given that the literature reports a 3-fold
improvement in potency for stapling the BIM peptide.15,41 The
constrained BIM peptides were also signicantly worse at
inhibiting the Mcl-1/FITC-NOXA-B interaction, with IC50 values
of 1.8 mM for BIM-MM and IC50 of 890 nM for BIM-DM
compared to an IC50 of 50 nM for BIM-WT (Fig. 4b).
Direct titration experiments were also performed for FITC
labelled BID peptides (Fig. 5). Fluorescence anisotropy was used
to measure direct binding with Bcl-xL titrated into each of the
FITC-labelled-modied-BID peptides. The data did not t well
to a 1 : 1 binding isotherm in these conditions, indicating the
presence of non-specic binding phenomena (possibly due to
the uorophore) and hence was tted using a logistic model.
FITC-BID-WT had an EC50 of 79 nM, with FITC-BID-MM and
FITC-BID-DM observed to bind with slightly reduced aﬃnity;
EC50 values of 186 nM and 159 nM. FITC-BID-Aib was observed
to have comparable binding EC50 ¼ 57 nM aﬃnity to the wild-
type. We also tested the direct binding of the BID peptides to
Mcl-1. In direct binding with Mcl-1 minimal changes in binding
aﬃnity were observed. Again FITC-BID-WT showed a highThis journal is © The Royal Society of Chemistry 2016
Fig. 3 BID peptide/protein titrations (a) ﬂuorescence anisotropy
competition assay for inhibition of Bcl-xL/BAK interaction, with Bcl-xL
at 131 nM and BODIPY-BAK at 43 nM (b) ﬂuorescence anisotropy
competition assay for inhibition of Mcl-1/NOXA-B interaction, with
Mcl-1 at 150 nM and FITC-NOXA-B at 50 nM (40 mM sodium phos-
phate, 200 mM sodium chloride, 0.02 mg ml1 bovine serum albumin,
pH 7.50).
Table 2 Fluorescence anisotropy competition, ﬂuorescence anisot-
ropy direct binding experiments for BID and BIM peptides
BH3 peptide
Bcl-xL/BODIPY-
BAK IC50
Mcl-1/FITC-
NOXA-B IC50
BID-WT 1.44  0.05 mM 0.39  0.08 mM
BID-MM 0.62  0.02 mM 1.6  0.12 mMa
BID-DM 1.14  0.04 mM 0.8 0.07 mM a
BID-AIB 1.14  0.05 mM N/D
BIM-WT 320  70 nM 50  2 nM
BIM-MM 11.9  3.8 mMa 1.8  0.25 mMa
BIM-DM 4  0.62 mMa,b 890  150
nMa,b
Bcl-xL EC50 Mcl-1 EC50
FITC-BID-WT 79  6 nM 98  8.9 nM
FITC-BID-MM 186  24 nM 153  12 nM
FITC-BID-DM 159  13 nM 129  3 nM
FITC-BID-Aib 57  16 nM 84  13 nM
a Two tailed p value withWT < 0.01. b Two tailed p value with MM < 0.02.
Fig. 4 BIM peptide/protein titrations (a) ﬂuorescence anisotropy
competition assay for inhibition of Bcl-xL/BAK interaction, with Bcl-xL
at 131 nM and BODIPY-BAK at 43 nM (b) ﬂuorescence anisotropy
competition assay for inhibition of Mcl-1/NOXA-B interaction, with
Mcl-1 at 150 nM and FITC-NOXA-B at 50 nM (40 mM sodium phos-
phate, 200 mM sodium chloride, 0.02 mg ml1 bovine serum albumin,
pH 7.50).
Fig. 5 BID peptide/protein titrations (a) ﬂuorescence anisotropy direct
binding assay for interaction of BH3 peptides with Bcl-xL (b) ﬂuores-
cence anisotropy direct binding assay for interaction of BH3 peptides
with Mcl-1 (50 mM tris, 140 mM sodium chloride, pH 7.50).
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View Article Onlineaﬃnity EC50 ¼ 98 nM, with EC50 ¼ 153 nM for FITC-BID-MM,
EC50 ¼ 129 nM for FITC-BID-DM and EC50 ¼ 84 nM for FITC-
BID-Aib.
The subtle diﬀerences in prole between the competition
and direct titrations are likely to arise as a consequence of
interaction of the labelled peptide being displaced with itself
and with other components present in the equilibrium (i.e. the
titrant peptide); this is not uncommon for FA competition
assays for which an analytical solution that distinguishes
between specic and non-specic eﬀects is not viable.46
In summary, only subtle diﬀerences were observed for the
inhibition of pro-apoptotic Bcl-xL and Mcl-1 interactions using
the pan-Bcl-2 binding BID sequence upon introduction ofThis journal is © The Royal Society of Chemistry 2016a hydrocarbon constraint. In contrast, a signicant loss of
inhibition of pro-apoptotic Bcl-xL and Mcl-1 interactions using
the pan-Bcl-2 binding BIM sequence upon introduction of
a hydrocarbon constraint was observed. The results also
demonstrate that constraining a peptide with a hydrocarbon
linker has diﬀerential eﬀects upon the selectivity and specicity
prole of Bcl-2 family recognition properties. Indeed, Walensky
and co-workers have noted that constraining peptides can give
target dependent results.5,47Structural properties of constrained peptides bound to Bcl-2
family proteins
To ascertain whether the constraint alters the recognition of the
hot-spot residues within the peptide, BID-MMwas co-crystallised
with Mcl-1. The resulting structure is the rst BID/Mcl-1 struc-
ture reported and the highest resolution structure seen thus far
with a hydrocarbon constrained peptide/target complex, at 1.43 A˚Chem. Sci., 2016, 7, 3694–3702 | 3697
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View Article Online(PDB entry 5C3F). When in complex with Mcl-1, the hydrocarbon
constraint in BID-MM is positioned away from the protein
surface, hence not contributing directly to binding (Fig. 6a and
b). The double bond within the constraint is in a cis congura-
tion, with no electron density to suggest that it exists in a trans
conguration (Fig. 6b, ESI Fig. S11†). BID-MM binds analogously
to BIM-WT in such a way that the constraint doesn't aﬀect the
positioning of the hot-spot residues (Fig. 6c). The salt bridge
between the conserved BH3 aspartic acid and a conserved argi-
nine in the BH1 domain of Mcl-1 is also retained.48
To ascertain whether the constraint also alters the recogni-
tion of the hot-spot residues within the BIM peptide, BIM-MM
was co-crystallised with Bcl-xL and the structure was rened to
2.45 A˚ (PDB entry 5C3G). The hydrocarbon constraint in BIM-
MM is also positioned away from the protein surface and in a cis
conformation (Fig. 6d, ESI Fig. S12†). The constraint itself
projects out into solvent and does not contribute to the inter-
action between the peptide and Bcl-xL (Fig. 6e). When compared
to the structure of Bcl-xL bound to BIM-WT and BIM-DM,43 there
are no signicant diﬀerences in the orientation of hot-spot side
chains or registry of the peptide (Fig. 6f) – therefore the reason
for the drop in potency is not explained by the static structure of
the bound complex.Kinetics of binding
Given that the constrained peptides adopted a more helical
conformation but did not exhibit increased potency, weFig. 6 Crystal structures of constrained peptide/protein interactions (a
interface illustrating cis double bond and key side chains (c) overlay of B
binding interface. Side chains from BID-MM are shown in green, with B
enlargement of Bcl-xL/BIM-MM interface illustrating cis double bond an
and BIM-DM (from PDB ID: 2YQ6) illustrating similarity of binding interf
chains in blue and BIM-DM side chains in yellow.
3698 | Chem. Sci., 2016, 7, 3694–3702expanded our study to include a more detailed investigation of
the kinetics and thermodynamics of binding. To investigate
how the hydrocarbon constraint aﬀects binding kinetics, we
established a surface plasmon resonance (SPR) based assay. Bcl-
xL was immobilised on a sensor chip via its N-terminal His-
SUMO tag. BID-WT and BID-MM were then owed over the
immobilised protein. The Kd, on and oﬀ rates were calculated
from the data tted to a 1 : 1model using an average of at least 3
sets of data recorded at various concentrations, all with chi-
squared values of below 10% of the Rmax (Table 3, Fig. 7, ESI
Fig. S13†). The aﬃnity of BID-MM was slightly lower than with
BID-WT, at 107 nM compared to 57 nM respectively. These
values are within one order of magnitude to those observed in
direct FA, which is reasonable given the presence of a FITC
uorophore for the latter. The on rate was altered, being 10
times slower for BID-MM (3.1  104 M s1 compared to 1.8 
105 M s1), whilst the oﬀ-rate was also diminished by nearly one
order of magnitude (3.0  103 s1 compared to 1.0  102 s1
with BID-WT). These experiments were repeated for the BIM
series of peptides. The on rate was also altered in this series of
peptides, being 10 times slower with BIM-MM and BIM-DM
(2.08  104 M s1 compared to 2.3  105 M s1 for BIM-WT).Thermodynamics of binding
We investigated the thermodynamics of binding using Van't
Hoﬀ analyses of uorescence anisotropy direct binding experi-
ments (Fig. 8). The full titration was recorded in triplicate at) Mcl-1/BID-MM (PDB entry 5C3F) (b) enlargement of Mcl-1/BID-MM
ID-MM and Mcl-1/BIM-WT from PDB ID: 2NL9 illustrating similarity of
IM-WT side chains in blue. (d) Bcl-xL/BIM-MM (PDB entry 5C3G) (e)
d key side chains (f) overlay of BIM-MM, BIM-WT (from PDB ID: 3FDL)
ace side chains from BIM-MM are shown in green, with BIM-WT side
This journal is © The Royal Society of Chemistry 2016
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View Article Onlineincreasing temperatures from 18 C to 43 C. The data could be
t to a 1 : 1 model permitting determination of Kd (see: ESI
Fig. S14 and S15†). The resultant data were plotted for 1/T
against ln Ka (Fig. 8) and used to estimate DH and DS.
Comparing the contributions of enthalpy and entropy to the
interaction (Fig. 8b), binding of FITC-BID-MM to Bcl-xL is
entropically more favourable than binding of FITC-BID-WT to
Bcl-xL, supporting the expectation that the entropic cost of
binding is reduced upon constraining. This is compensated for
by an opposing change to the enthalpic contributing to binding.
This behaviour is entirely consistent with many co-operative
biomolecular protein–ligand interactions.49Fig. 7 Surface plasmon resonance (SPR) sensorgram of BIM peptides
at 100 nM interacting with immobilised Bcl-xL.Discussion
The folding of a polypeptide into an ordered conformation is
dependent upon enthalpic contributions from backbone or side
chain hydrogen-bonding,50 other electrostatic forces (e.g. p–p
stacking) and the hydrophobic eﬀect counterbalanced against
entropic contributions from xing chain entropy and solvent
reorganisation. These two large opposing thermodynamic
values result in only marginal stability of the folded form45
whereby the magnitude of any single non-covalent interaction
may be comparable in magnitude to the overall DG of folding.
Outside the context of a folded tertiary structure, in solution,
short a-helical peptides usually exist in a random coil or
intrinsically disordered conformation.45 a-Helix formation
occurs through initial nucleation in a region of the helix, fol-
lowed by propagation throughout the entire sequence (the
Zimm–Bragg theory);45,51 for short peptides, the entropic cost of
helix nucleation is not oﬀset by favourable enthalpic gains from
newly formed non-covalent interactions during nucleation and
propagation.52 In the simplest sense, by introducing
a constraint into a peptide that biases its structure towards its
bioactive helical conformation, the “cost” of nucleation should
have already been paid and for subsequent interaction with
a partner protein, the overall aﬃnity for the target of the peptide
should increase. An upper limit on what might be achieved in
terms of potency enhancement can be estimated to match
closely the diﬀerence in stability (DDG) between the constrained
and non-constrained sequences (which we estimate here to be
<3 kJ mol1). However, this represents an oversimplication;
the constraint on the peptide may make productive non-cova-
lent interactions47 or introduce steric clashes53 with the partner
protein. Moreover, the mechanism of folding (Fig. 9) has
recently been proposed to inuence binding aﬃnity; for theTable 3 SPR analysis of constrained peptides binding to Bcl-xL
BH3 peptide Bcl-xLkon
BID-WT 1.8  106 M s1  0.42  106 M s1
BID-MM 3.1  104 M s1  0.9  104 M s1
BID-DM 1.75  104 M s1  0.3  104 M s1
BIM-WT 2.3  105 M s1  6.3  10 4 M s1
BIM-MM 2.08  104 M s1  0.7  104 M s1
BIM-DM 2.09  104 M s1  1.8  104 M s1
This journal is © The Royal Society of Chemistry 2016interaction between Mcl-1 and PUMA,54,55 mutations within
PUMAmodulated the residual helicity, but not the aﬃnity of the
peptides towards Mcl-1.54,55 Furthermore, more helical PUMA
variants were shown to bind and unbind from Mcl-1 more
slowly. Conformational selection suggests that the target
protein only recognises the peptide when it briey forms
a helical structure, whereas an induced t mechanism of
binding occurs where an unstructured peptide is recognised
and folds on the binding surface.56 For conformational selec-
tion a greater proportion of the bioactive conformer might
reasonably be expected to result in a more eﬃcient interaction
with its target whereas for induced-t, the constrained (pre-
organised) peptide might have more limited “ways to bind”57 or
may interfere with the binding pathway.
Our SPR studies reveal in all cases a signicant decrease in
on and oﬀ rates for binding to Bcl-xL when either BID or BIM are
constrained. This (i) is consistent with an induced t “bind-and-
fold” mechanism, (ii) suggests this binding mechanism is
general to Bcl-2 family interactions (and not limited to PUMA/
Mcl-1) and (iii) suggests for the rst time that covalently con-
straining a peptide can have similar consequences to binding
kinetics as are observed when non-covalent forces are used to
bias conformation. However, the binding mechanism need not
inuence binding thermodynamics; our Van't Hoﬀ analyses
indicate that constraining leads to more entropically favourable
binding but this is oﬀset by an opposing change in enthalpy.
Okamoto and colleagues interpret the reduced binding aﬃnity
of BIM peptides constrained using a,a0-disubstituted amino
acids towards Bcl-xL and Mcl-1 as arising due to loss ofBcl-xLkoﬀ Bcl-xLKd
1.0  102 s1  0.18  102 s1 57 nM  16 nM
3.0  103 s1  0.7  103 s1 107 nM  29 nM
3.0  103 s1  1.0  103 s1 178 nM  52 nM
9  103 s1  0.9  103 s1 44 nM  17 nM
8  10 3 s1  0.8  10 3 s1 460 nM  232 nM
9.7  103 s1  0.9  103 s1 1.6 mM  0.8 mM
Chem. Sci., 2016, 7, 3694–3702 | 3699
Fig. 8 (a) van't Hoﬀ analysis of FITC-BID-WT and FITC-BID-MM
interacting with Bcl-xL, (50 mM HEPES pH 7.5, 200 mM NaCl, 0.05%
Tween 20, recorded at 18-43 C). (b) Thermodynamic signatures of
WT and MM BID peptides binding to Bcl-xL.
Fig. 9 Schematics depicting diﬀerent binding mechanisms available
for Bcl-2 family/BH3 helix mediated PPIs.
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View Article Onlinefavourable intramolecular non-covalent side-chain interactions
within the peptide upon binding Bcl-xL or Mcl-1. However, these
“lost” interactions are not needed in the constrained peptide
and make no direct favourable enthalpic contacts with the
target protein. With our X-ray crystallographic analysis sug-
gesting that the bound states of the constrained and uncon-
strained systems studied here are similar, the thermodynamic
binding behaviour can be better accounted for by considering
the unbound peptides rather than the protein–peptide complex.
While the constrained peptide will have lower entropy as
a result of pre-organisation, the backbone hydrogen-bonding is
also already present giving a more enthalpically favourable
starting condition. Conversely the unconstrained more disor-
dered system has a higher entropy in the unbound state,
however this is oﬀset by the absence of favourable backbone
hydrogen bonding interactions which are only gained on3700 | Chem. Sci., 2016, 7, 3694–3702formation of the unconstrained-ligand/protein complex. If these
entropic and enthalpic diﬀerences in the unbound states
balance then their free energies will be identical and, with nearly
identical bound states, the overall binding energies will also be
similar. Thus, making an assumption that constraining
a peptide changes the energetic state relative to theWT sequence
is not valid as the sequences are diﬀerent. Although the helical
state is preferred in the constrained system this can be consid-
ered to be due to an increase in the energy of the unfolded state
rather than due to absolute preorganization of the helical
conformation relative to the unconstrained sequence.
Conclusions
In summary, we have illustrated that a-pentylglycine represents
a powerful amino acid with which to introduce a hydrocarbon
constraint, with the advantage of being easier to synthesise and
couple during peptide synthesis. Crystal structures of Mcl-1/
BID-MM and Bcl-xL/BIM-MM revealed that the constrained
peptides adopt comparable binding conformations when
compared to available structures with wild type sequences and/
or peptides constrained with the a,a0-disubstituted alkenyl
amino acids. Furthermore our structures conrm that the
constraints point away from the BH3 binding cle and do not
introduce steric constraints or new non-covalent interactions
with the anti-apoptotic partner. Additional biophysical studies
using SPR and van't Hoﬀ analyses are consistent with an
induced t binding mechanism and enthalpy–entropy
compensation. This contradicts the hypothesis that introduc-
tion of a constraint to pre-organise a peptide should enhance its
protein binding aﬃnity. More generally, these studies under-
score the need to probe carefully the eﬀects of pre-organisation
on protein–ligand interactions – where the constraint is intro-
duced on a ligand that can readily adopt its bioactive confor-
mation and already has optimal binding interactions, it is
unlikely to positively inuence the binding potency.
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